Buscar resultados de ensayos clínicos
Membranous Nephropathy - 29 Studies Found
Estado | Estudiar |
Withdrawn |
Nombre del estudio: Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Condición: Glomerulonephritis, Membranous Fecha: 2013-01-04 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Study on the Therapeutic Effect of TCM Treatment for MDR MN Condición: Idiopathic Membranous Nephropathy Fecha: 2015-11-18 Intervenciones: Drug: Jianpixiaozhong particles and Wuse Dietotherapy Jianpixiaozhong particles: Three packs once,bid po |
Completed |
Nombre del estudio: Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Condición:
Fecha: 2006-11-27 Intervenciones: |
Completed |
Nombre del estudio: Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Condición:
Fecha: 2006-08-09 Intervenciones: Drug: tacrolimus combined with prednisone |
Completed |
Nombre del estudio: Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy Condición:
Fecha: 2002-12-17 Intervenciones: Drug: Sirolimus |
RECRUITING |
Nombre del estudio: Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy Condición: Fecha: 2024-05-18 |
NOT_YET_RECRUITING |
Nombre del estudio: REmission in Membranous Nephropathy International Trial (REMIT) Condición: Primary Membranous Nephropathy Fecha: 2024-05-18 Intervenciones: Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.Prior to the administration of obinutuzum |
RECRUITING |
Nombre del estudio: A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy Condición: Primary Membranous Nephropathy Fecha: 2024-05-18 Intervenciones: Participants will receive zanubrutinib once daily |
RECRUITING |
Nombre del estudio: A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy Condición: Primary Membranous Nephropathy Fecha: 2024-05-18 Intervenciones: Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product. |